Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 14, 2025, at 8:00 AM PT/11:00 AM ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A recording of the presentation will remain available on the company's website for a minimum of two weeks after the event.

CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET.

The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:

Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com

FAQ

When is Agios Pharmaceuticals (AGIO) presenting at the BofA Securities Healthcare Conference 2025?

Agios Pharmaceuticals will present at the BofA Securities Healthcare Conference on Wednesday, May 14, 2025, at 8:00 AM PT/11:00 AM ET.

How can investors access Agios Pharmaceuticals' (AGIO) BofA Securities conference presentation?

Investors can access the live webcast through the Investors section of Agios' website (www.agios.com) under the 'Events & Presentations' tab.

How long will Agios Pharmaceuticals' (AGIO) BofA Securities conference presentation be available for replay?

The webcast replay will be archived on Agios' website for at least two weeks following the presentation.

What is Agios Pharmaceuticals' (AGIO) main business focus?

Agios Pharmaceuticals is a leader in cellular metabolism and PK activation, focusing on pioneering therapies for rare diseases.